BLRX - BioLineRx launches mid-stage combo study in first-line pancreatic cancer

BioLineRx (BLRX) perks 7% premarket after announcing that its lead drug candidate, the CXCR4-inhibitor Motixafortide, will be tested in combination with the anti-PD-1 cemiplimab (LIBTAYO) and standard-of-care chemotherapy (gemcitabine and nab-paclitaxel) in first-line metastatic pancreatic ductal adenocarcinoma ((PDAC)). The Phase 2 study will initially enroll 10-12 PDAC patients, and will be expanded to a total of 40 patients following an evaluation of the initial 10-12 patients based on pre-defined criteria.The primary endpoint is the overall response rate. Secondary endpoints include safety and tolerability, progression free survival, duration of clinical benefit and overall survival. Data from the study are anticipated in mid-2022.

For further details see:

BioLineRx launches mid-stage combo study in first-line pancreatic cancer